Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients
- 1 October 1996
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 135 (4) , 538-544
- https://doi.org/10.1111/j.1365-2133.1996.tb03827.x
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisalBritish Journal of Dermatology, 2006
- Abnormalities of serum type III procollagen aminoterminal peptide in methotrexate-treated psoriatic patients with normal liver histology do not correlate with hepatic ultrastructural changesBritish Journal of Dermatology, 1995
- Serum aminoterminal propeptide of type III procollagen in psoriasis and psoriatic arthritis: Relation to liver fibrosis and arthritisJournal of the American Academy of Dermatology, 1991
- Methotrexate in psoriasis: Revised guidelinesJournal of the American Academy of Dermatology, 1988
- PROCOLLAGEN-III-PEPTIDE AND HYRERTHYROIDISMThe Lancet, 1986
- Complications following percutaneous liver biopsyJournal of Hepatology, 1986
- The N-terminal propeptide of collagen type III in serum as a prognostic indicator in primary biliary cirrhosisJournal of Hepatology, 1986
- The Blue Glass and the Predictive Value of Serum Amino-Terminal Propeptide of Type III Procollagen as a Marker of Liver FibrosisHepatology, 1984
- Methotrexate guidelines—revisedJournal of the American Academy of Dermatology, 1982
- Liver Biopsies in Psoriatics Complications and EvaluationInternational Journal of Dermatology, 1980